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ABSTRACT 
 
The use of chemically-synthesized short interfering RNAs (siRNAs) is the key method of choice to 
manipulate gene expression in mammalian cell cultures and in vivo. Several previous studies have aimed at 
inducing cell-specific RNA interference (RNAi) in order to use siRNA molecules as therapeutic reagents. 
Here, we used peptide-inhibited siRNAs that were activated after cleavage by cell-specific peptidases. We 
show that siRNAs with bound peptide at the antisense strand could be activated in target cells and were able 
to induce RNAi in a cell-specific manner. Green Fluorescent Protein (GFP) and Signal Transducer and 
Activator of Transcription (STAT)-3 gene expression were selectively reduced in a JEG-3 human 
choriocarcinoma cell line expressing the activating enzyme caspase-4, whereas the effect was absent in HEK 
cells which lacked the enzyme. In JEG-3 cells, reduction of STAT3 gene expression by conventional and 
peptide-inhibited siRNA led to a decrease in cell proliferation. This suggests that peptide-inhibited siRNAs 
provide improved cell specificity and offers new opportunities for their therapeutic use.  
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INTRODUCTION 
 
RNAi-based strategies are among the leading 
methodologies to silence gene expression in mammalian 
cells. Typically, 21-bp dsRNA molecules, termed short 
interfering RNAs (siRNAs), with perfect 
complementarities in one strand to the target mRNA, are 
used to induce RNAi (Elbashir et al, 2001). Upon delivery 
into the cell, siRNAs are incorporated into the RNA-
induced silencing complex (RISC) containing the 
signature component of the RNAi machinery, Argonaute 2 
(Ago2) (Hammond et al, 2001; Martinez et al, 2002; 
Maniataki and Mourelatos, 2005). The siRNA strand 
containing the thermodynamically less stable 5’end, the 
antisense strand (AS), is preferentially incorporated as the 
guiding strand of RISC (Khvorova et al, 2003; Schwarz et 
al, 2003), while the sense strand (SS) of the siRNA duplex 
is cleaved by Ago2 and liberated (Matranga et al, 2005; 
Rand et al, 2005; Leuschner et al, 2006). This generates 
the activated RISC containing the guiding antisense strand, 
which binds the complementary target mRNAs and leads 
to their cleavage by Ago2 (Liu et al, 2004). Whereas 
unmodified siRNAs are highly efficient in cultured cells, 
chemical modification is generally considered to be a 
prerequisite for fulfilling the potential of siRNAs in vivo: 
Successful experiments in animal models have frequently 
relied upon injection of chemically-modified siRNAs 
(Lorenz et al, 2004; Soutschek et al, 2004; Mack et al, 423 
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2005). Modifications of siRNAs mostly aim at achieving 
better intracellular delivery (Soutschek et al, 2004) or 
enhanced nuclease resistance (Mack et al, 2005). Some 
chemical modifications of siRNAs include conjugation to 
lipids (Soutschek et al, 2004; Lorenz et al, 2004) and 
membrane-penetrating peptides (Muratovska and Eccles, 
2004), or RNA aptamer sequences (McNamara et al, 
2006). These modified siRNAs with superior potency 
require lower doses for gene silencing (Allerson et al, 
2005; Elmen et al, 2005; Schulz et al, 2009), and specific 
chemical modifications reduce siRNA side-effects, such as 
the induction of recipient immune responses and inherent 
off-target effects (Vollmer et al, 2004). 
 
In general, in vivo siRNA delivery is difficult. Another 
hurdle for its pharmaceutical use is to deliver siRNA 
exclusively into the target tissue. Known strategies for 
cell- or tissue-specific siRNA delivery, e.g., using 
receptor-ligand systems or aptamer structures, also lead to 
the induction of RNAi in other cells by non-specific 
siRNA uptake, though on a lower level (Yutaka and 
Kazunari, 2006). Here, we demonstrate the proof-of-
principle for a mechanism to provide a key-lock-approach 
to siRNA molecules in order to induce RNAi specifically 
in the target cells. 
 
MATERIALS AND METHODS 
 
Peptide synthesis 
The peptide Fmoc-LE(OFm)VD(OFm)G-OH was 
synthesized manually by a combination of solution and 
solid-phase synthesis. The dipeptides H-E(OFm)V-OH 
and H-D(OFm)G-OH were prepared using a chlorotrityl 
chloride resin (500mg). The Asp and Glu derivatives were 
used in the Boc-N
a-protected version (Bachem, 
Bubendorf, Switzerland), while all other amino acid 
derivatives were used in the Fmoc-protected form. 
Coupling reactions were performed using the amino acids 
(4eq) activated with HBTU (4eq) and DIEA (8eq) in DMF 
for 0.5-1hr (double couplings). Fmoc removal during 
solid-phase synthesis was effected by treating the resin 
twice with 20% (v/v) piperidine in DMF for 5min and 
15min, respectively. Cleavage of the Boc-protection was 
accomplished concomitantly with peptide removal from 
the resin using TFA/water/triisopropylsilane (95:2.5:2.5) 
for 3hr at room temperature. The crude peptides were 
precipitated in diethyl ether, centrifuged and washed three 
times with diethyl ether. The yields of crude dipeptides 
were between 70-80%. Following introduction of Fmoc-
Leu-F in H-E(OFm)V-OH according to a procedure 
described earlier (Müller et al, 1999; Ananda et al, 2000), 
the resulting tripeptide was coupled to H-D(OFm)G-OH in 
solution using TFFH as coupling reagent as reported 
(Carpino and El-Fahan, 1995). The crude pentapeptide 
Fmoc-LE(OFm)VD(OFm)G-OH was purified by reversed-
phase HPLC on a Shimadzu LC-10AT chromatograph 
(Duisburg, Germany) with a Vydac 218TP column (5µm 
particle size, 300Å pore size, 4.6x25mm). Peptides were 
eluted with a gradient of 20-90% eluent A and B within 
70min at a flow rate of 1.0ml/min, where A was 0.1% 
(v/v) TFA in water and B 0.1% (v/v) TFA in acetonitrile; 
detection was at 220nm. The molar masses of all peptides 
were determined by MALDI-TOF mass spectrometry on a 
Laser Tec Research mass spectrometer (Perseptive 
Biosystems, Weiterstadt, Germany) using cyano-4-
hydroxycinnamic acid as matrix.  
 
siRNA-peptide conjugation 
The described pentapeptide carrying protecting Fmoc-
groups was dissolved in dioxane and activated by 
pentapeptide-NHS-ester with equimolar amounts of NHS 
and DCC. 
  
To produce PI-siRNA, the siRNA five prime end antisense 
strand was modified with an aminohexyl group 
(Eurogentec, Belgium). Because of intrinsic peptide 
chemistry and selection of the protecting Fmoc-groups, the 
peptide will only bind to the linker structure on the siRNA.  
For conjugation, a quintuple excess of pentapeptid-NHS-
ester (dissolved in dioxane) was mixed with one amount of 
modified siRNA single strand at room temperature for 
1.5hr. After lyophilization, the protecting Fmoc-groups 
were cleaved by adding DMF and diethylamine, the 
resulting PI-siRNA was dialyzed and lyophilized again. 
 
siRNA and PI-siRNA single strands were separately 
diluted with RNAse free water and annealed by incubation 
at 95
oC for 3min followed by 37
oC for 1hr in annealing 
buffer (Eurogentec, Belgium).  
 
Cell lines 
JEG-3 is an adherent human placental choriocarcinoma 
cell line, which maintains several trophoblast-like 
capacities including production of pregnancy related 
hormones. This cell line was purchased from ATCC 
(USA, ATCC No: HTB-36™). HEK is a standard adherent 
human embryonic kidney cell line, purchased from ATCC 
(USA, ATCC No: CRL-1573™). For GFP-siRNA 
experiments, both cell lines were transfected with GFP-
plasmid (Clontech, USA) using electroporation (1150V, 
10ms, 2 pulses) (Microporator MP-100, Peqlab, Germany) 
and selected by using neomycine resistance (Sigma, USA).  
 
Cell culture 
All cultures were commenced at 10
6 cells/175cm
2 flask, 
and maintained under standardized cell culture conditions 
(37
oC, 5%, v/v, CO2, humidified atmosphere) in DMEM 
medium (Dulbecco’s Modified Eagle Medium; Cambrex, 
U.K.) containing L-glutamine (Gibco, USA) supplemented 
with 10% (v/v) fetal calf serum (FCS; Gibco, USA) and 
2% (w/v) antimycotic-antibiotic solution (AAS, Sigma, 
Germany). Cells were trypsinized when confluence was 
estimated to be over 75%.  
 
Analysis of caspase-4 activity 
A total of 10
6 cells were cultured in 6-well plates at 50% 
confluency. Medium was removed and 1ml fresh medium 
was given into each well. 20µl of caspase-4 substrate (L-
E-V-D-G-AFC, MoBiTec, Germany, 20mM) was added to 
the medium. After 4hr of incubation at standard 
conditions, medium was removed; cells were washed with 
1ml HBSS and lysed in 100µl of lysis buffer (20mM 
HEPES, 2mM EGTA, 0.2mM EDTA, 0.12M NaCl, 1%, 
v/v, Triton-X 100) supplemented with protease inhibitors 
(5mM beta-glycero- phosphate, 3mM MgCl2, 20mg/ml 
aprotinine (trasylol), 20mg/ml leupeptine, 5mg/ml 424 
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pepstatine A, 647ng/ml anti-pain, 10mg/ml bestatine, 
0.1mM PMSF, 1mM sodium orthovanadate). Afterwards, 
cell lysates were analyzed for cleaved fluorometric 
substrate by using HPLC and fluorescence detector as 
described by Koehn et al (2008). 
 
RNA interference 
Oligonucleotides were designed to interfere exclusively 
with GFP mRNA (Eurogentec, Belgium) or STAT3 
mRNA (sequence: 5’AAT GTT CTC TAT CAG CAC 
AAT) as described elsewhere (Poehlmann et al, 2005). As 
a negative control, the same nucleotides were scrambled to 
form a non-genomic sequence (Sequence: 5’AAG CCA 
CTT ATA AAT TCG TTC; Eurogentec, Belgium). In the 
previous studies, the used siRNA sequences showed 
efficient silencing rates and no off-target effects 
(Poehlmann et al, 2005). During electroporation, 21-
nucleotide siRNA and PI-siRNA duplexes were applied at 
a concentration of 1µM (in electroporation pipette; final 
concentration in cell culture was 10nM); siRNA delivery 
using RiboJuice transfection reagent (Merck, Germany) 
was performed at a final concentration of 5nM. For 
electroporation, cells were trypsinized and washed with 
HBSS. After centrifugation, cell pellets were resuspended 
in 100µl cell resuspension buffer (Peqlab, Germany). 1µl 
of control, target-gene siRNA or PI-siRNA solution 
(100µM) was added to cells and electroporation was 
performed in 2 pulses at 1100V for 35ms (Microporator 
MP-100). After the electroporation procedure, cells were 
cultured in 6-well plates with 2ml DMEM medium per 
well. For siRNA delivery using RiboJuice transfection 
reagent, cells were cultured in 6-well plates in standard 
DMEM medium. At 70% confluency, cells were washed 
with PBS and 1ml new DMEM medium was added. A 
volume of 2µl RiboJuice was added to peptide-inhibited or 
conventional siRNA (1µM) and incubated for 20min at 
room temperature. Afterwards samples were applied to 
cells. Analyses were performed 24-96hr after transfection.  
 
Caspase-4 inhibition 
JEG-3 cells were cultured under standard conditions and 
prepared for siRNA transfection as described above. 
Caspase-4 inhibitor (Z-YVAD-FMK; R&D Systems, 
USA) was applied to JEG-3 cells during siRNA 
transfection at a final concentration of 200nM. 
 
Flow cytometry 
GFP transfection efficiency and RNAi were analysed 
using flow cytometry. Cells were cultured in 6-well plates, 
washed with PBS and trypsinized. DMEM-medium 
supplemented with 10% (v/v) fetal calf serum (FCS; 
Gibco, USA) and 2% (w/v) antimycotic-antibiotic solution 
(AAS, Sigma, Germany) was added to stop trypsin 
activity. Fluorescence intensity and the number of GFP 
positive cells were assessed using a FACSCalibur (BD, 
USA) and Cellquest Pro software (BD, USA). 
 
Polyacrylamide gel electrophoresis (PAGE) and 
western blot 
A number of 2x10
6 cells were cultured in 6-well plates, 
washed with PBS containing proteinase inhibitors and 
scraped from the culture plates. After centrifugation, cell 
pellets were suspended in 100µl lysis buffer supplemented 
with protease inhibitors. Protein concentrations of cell 
lysates were determined using a kit based on the Bradford 
method (Sigma, USA). 20mg of whole cell extract was 
solublized in gel loading buffer (62.5mM Tris/HCl pH 6.8; 
2%, w/v, SDS; 25%, v/v, glycerol; 1% (w/v) phenol blue; 
5% (v/v) beta-mercaptoethanol), denatured for 5min and 
separated on 10% (w/v) acrylamide-SDS gels (Serva, 
Germany). After protein transfer, nitrocellulose 
membranes were blocked in NET-G buffer (150mM NaCl, 
50mM Tris-HC1, 5mM EDTA, 0.25%, w/v, gelatin;. pH 7.4) for 
1hr. Antibodies against STAT3 (Cell signaling, USA) 
were applied for 12hr at a 1:1000 dilution. For detection, 
peroxidase-conjugated anti-rabbit IgG (New England 
Biolabs, USA) was employed at a dilution of 1:10,000 for 
1hr. Visualisation was performed using a LumiGlo 
Chemiluminescence reagent (New England Biolabs, 
USA). Protein loading control of western blots was 
performed by application of anti-tubulin antibodies 
(Sigma, USA) following the same detection procedure as 
described for STAT3. All western blots were repeated 3 
times and were analyzed and quantified by Totallab TL100 
software, version 2008. 
 
Proliferation assay 
24hr after transfection, cells were trypsinized and counted 
by a flow cytometry method (Beckman Coulter, USA). 
Briefly, 20,000 cells were plated in 12-well plates and 
incubated for 48hr. Then cells were trypsinized and 
counted again. Proliferation index (PI) was calculated by 
the following formula: 
 
PI = log2(cell number/20.000) 
 
The assays were done in duplicates and repeated twice. 
 
Statistics 
To investigate the significance of the results a paired t-test 
was performed. Differences between samples were defined 
as significant, for p<0.05; p<0.01 were defined as highly 
significant. 
 
RESULTS 
 
Experimental design 
We generated siRNA that induces RNAi specifically in 
target cells. The enabling mechanism to induce specificity 
relies on the activation of a peptide-inhibited siRNA (PI-
siRNA) by cell-specific active peptidases (Figure 1). 
Since binding of sterically large structures (e.g., peptides) 
to the backbone of the siRNA antisense strand reduces the 
induction of RNAi (Chiu and Rana, 2003), a complete 
inhibition of the siRNA by an oligopeptide was 
attempted. After peptide cleavage a small chemical group 
should remain on the siRNA in order to minimize its 
influence on the siRNA activity. Therefore, an 
aminohexyl linker was used to conjugate the specific 
target peptide for caspase-4 with the siRNA (Figure 2a) 
and the very same peptide sequence was used to analyse 
caspase-4 activity. After peptide cleavage, the aminohexyl 
linker and the glycine residue should remain attached to 
the siRNA (Figure 2b). In non-target cells (Figure 1) the 
peptide-siRNA-chimera remains stable without inducing 
RNAi to a significant level. 425 
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Figure 1. Mechanism of peptide-inhibited – peptidase activated siRNA. For peptide-inhibited siRNA, an enzyme target sequence (in 
this case specific for caspase-4) is covalently bound to the siRNA antisense strand via an aminohexyl linker molecule. In JEG-3 cells, 
caspase-4 is active and cleaves the target peptide from the siRNA. The activated siRNA is still carrying the linker molecule and a 
glycine residue from the target peptide. In HEK cells, which show no caspase-4 activity, the bound peptide inhibits the siRNA 
function. 
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B: 
 
 
 
 
 
 
 
 
 
In order to test the described concept, the two cell lines 
JEG-3 and HEK were used because of their similar 
characteristics regarding siRNA transfection and their 
presumed difference in caspase-4 activity. The 
differentially-expressed enzyme is well suited for being 
used with the PI-siRNA strategy as it cleaves its target 
peptide L-E-V-D-G between aspartic acid and glycine, 
leaving only the small glycine residue at the siRNA linker 
after peptide cleavage. We tested the proteolytic activity of 
caspase-4 and produced two PI-siRNAs. GFP and STAT3 
were chosen as target genes and the caspase-4 target 
sequence was chosen as bound peptide. After the protein 
expression analyses, proliferation of JEG-3 cell including 
subsequent transfection of PI-siRNAs was analysed. 
Additional time dependent STAT3 expression analysis 
was performed in order to investigate the level of PI-
siRNA activation and to compare its induction kinetics 
with that of conventional siRNA. Furthermore, a rescue 
experiment inhibiting Caspase-4 in JEG-3 cell would 
support the enzymatic activation of the PI-siRNA concept. 
 
PI-siRNA synthesis  
An aminohexyl linker was chosen for conjugation to 
obtain a stable bond between the peptide and the siRNA 
antisense strand. The coupling chemistry used aimed at, (i) 
high binding efficacy of the peptide to the siRNA in order 
to prevent unspecific siRNA effects, and, (ii) siRNA 
stability in order to prevent siRNA degradation. The 
predicted chemical structure of the desired PI-siRNA was 
analysed by MALDI-TOF mass spectrometry and gel 
electrophoreses independently confirmed the high 
coupling rate (data not shown).  
 
Caspase-4 activity in JEG-3 and HEK cells 
By using a synthetic, fluorochrome-labelled caspase-4 
substrate, the peptidase activity in the cytoplasm of JEG-3 



Caspase-4
siRNA
Caspase-4 
target peptide
Peptide-Inhibited siRNA
Peptide cleavage
siRNA activation
no Caspase-4, 
but other enzymes
siRNA
Caspase-4 
target peptide
Peptide-Inhibited siRNA
no cleavage
no siRNA activation
Figure 2. Chemical structure of 
peptide-inhibited and peptidase-
activated siRNA. The target 
peptide for caspase-4 was bound 
to the siRNA antisense strand via 
an aminohexyl linker structure 
(A). The activated siRNA still 
contains the linker structure and a 
peptide residue (B). 426 
 
©The Authors | Journal of RNAi and Gene Silencing | December 2010 | Vol 6, No 2 | 422-430 | OPEN ACCESS 
and HEK cells was analysed via HPLC by measuring the 
free fluorochrome after cleavage. JEG-3 cell lysates 
showed a measurable enzyme activity (cleavage of 26 
pmol/ml cleaved substrate in the cell lysates), whereas no 
cleavage of caspase-4 substrate was detected in HEK cells 
(Figure 3). 
 
Cell-specific gene silencing by peptidase-activated 
siRNAs 
Conventional siRNAs reduced GFP expression by 51.4% in 
JEG-3 and by 79.3% in HEK cells, as compared to non-
genomic scrambled control siRNA (Figure 4). PI-siRNA 
molecules induced a GFP silencing efficacy of 26.6% in 
JEG-3 cells, while no silencing was detected in the caspase-
4-negative HEK cells. As anticipated, GFP siRNA silencing 
was exclusively induced in caspase-4 positive JEG-3 cells, 
although the RNAi effect was weaker than expected. 
  
Similarly, STAT3 PI-siRNA knock-down was specific to 
JEG-3 cells. Figure 5a shows the western blot analysis 
indicating the cell-specific silencing effect of PI-siRNA. 
As shown by the arithmetic mean of three independent 
western blots (Figure 5b), conventional siRNAs were able 
to reduce STAT3 expression by around 90% in JEG-3 and 
by 75% in HEK cells; whereas PI-siRNA decreased 
STAT3 expression in JEG-3 cells by 70% and 13% in 
HEK cells. 
 
Analysis of JEG-3 cell proliferation after STAT3 silencing 
We aimed at analyzing the modulation of cell proliferation 
after STAT3 silencing induced by conventional STAT3 
siRNAs and PI-siRNAs. Our results indicate that cells 
treated with conventional and PI-siRNAs showed a similar 
reduction of cell proliferation (PI=4.8) as compared to 
those transfected with control siRNA (PI=5.2) (Figure 6).  
 
Analysis of activation kinetics of peptidase-activated 
siRNAs 
To exclude an influence of the transfection method on the 
activity data for peptide-inhibited siRNA, a chemical 
siRNA delivery agent was used. In general the same 
effects were obtained as for the electroporation approach. 
To investigate the kinetics of peptidase activation, we 
analysed STAT3 silencing rates 48hr, 72hr and 96hr post- 
transfection (Figure 7). In JEG-3 cells conventional siRNA 
was active during the whole period of 96hr, whereas in 
HEK cells STAT3 expression returns to the normal level 
at 96hr. Using a chemical delivery method both, peptide 
inhibited and conventional siRNA, display maximal 
efficacy at 72hr in JEG-3 target cells. In contrast to 
conventional siRNA, the gene expression becomes 
elevated again after 96hr in JEG-3 cells. In non-target 
HEK cells PI-siRNAs remained inactive and did not 
induce detectable RNAi. 
 
Specific inhibition of Caspase-4 in JEG-3 cells  
In order to investigate whether the silencing effect in JEG-
3 cells was due to PI-siRNA activation by capase-4 or due 
to unspecific peptide degradation, a caspase-4 inhibitor 
was delivered to JEG-3 cells together with PI-siRNAs. By 
inhibiting the caspase-4 pathway, only conventional 
siRNAs reduced STAT3 expression, whereas PI-siRNAs 
was unable to induce RNAi (Figure 8). 
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Figure 3. Analysis of caspase-4 enzyme activity in HEK and 
JEG-3 cells. The fluorochrome-labelled target peptide for 
caspase-4 was applied to JEG-3 and HEK cells. After 
intracellular peptide cleavage, the free fluorochrome, which is a 
measure of the enzyme activity, was analysed by HPLC. The 
figure shows the arithmetic mean of 3 independent experiments 
and the calculated standard error.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Analysis of GFP expression in HEK and JEG-3 cells 
after transfection of GFP siRNA and PI-siRNA. A GFP 
expression vector was applied to JEG-3 and HEK cells, followed 
by transfection of siRNAs and PI-siRNAs targeting GFP. GFP 
fluorescence was analysed by flow cytometry 24hr after 
transfection. The chart shows arithmetic mean of 5 independent 
experiments and the calculated standard error. The fluorescence 
intensity of the control-siRNA sample was standardized to 100%. 
 
 
 
DISCUSSION 
 
Peptide-inhibited-peptidase-activated siRNAs exhibit a 
new mechanistic alternative to obtain cell-specific 
activation of siRNA molecules in target cells (Figure 1). 
The challenge of this strategy is to find a target peptidase 
with cell-specific activity, which is able to activate the 
siRNAs by peptide cleavage. Therefore, a dual cell line 
experiment (JEG-3 and HEK cells) using caspase-4 as 
peptidase was performed to show the feasibility of the 
concept. The system was chosen because of the enzyme 
properties (cleavage site at the end of the target peptide) 
and the fact that caspase-4 is expressed in JEG-3 cells 
(Fitzgerald et al, 2005), but according to microarray data 
does not show significant expression in kidney cells. After 
peptide cleavage, a remaining glycine residue and an amino- 
hexyl linker are left attached to the siRNA antisense strand 
0
20
40
60
80
100
120
140
JEG-3 HEK
r
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
 
i
n
 
%
Ctrl siRNA
GFP siRNA
GFP PI-siRNA427 
 
©The Authors | Journal of RNAi and Gene Silencing | December 2010 | Vol 6, No 2 | 422-430 | OPEN ACCESS 
 
 
Figure 5. STAT3 protein expression in HEK and JEG-3 cells after 
transfection of conventional siRNA and PI-siRNA. Conventional 
as well as peptide-inhibited siRNAs were applied to JEG-3 and 
HEK cells. After 24hr, STAT3 protein was detected by western 
blotting using α-tubulin as a loading control. A. A representative 
western blot. B. Arithmetic mean of 3 independent western blots 
and the calculated standard error. The STAT3 content of the 
control-siRNA sample was standardized to 100%. 
 
 
 
     
 
 
 
Figure 6. Analysis of JEG-3 cell proliferation after transfection of 
STAT3 siRNAs and PI-siRNAs. Conventional as well as peptide-
inhibited siRNA were applied to JEG-3 cells, followed by analysis 
of proliferation for period of 48hr. Cells were counted by flow 
cytometry, and the PI (corresponding to the number of cell 
divisions) was calculated. Arithmetic mean of 3 independent 
experiments and the calculated standard error are shown.  
 
 
(Figure 2b). The full caspase-4 target pentapeptide should 
prevent gene silencing since the five prime terminus of 
guide strands bind to PIWI domain of AGO2 protein, 
which is critical to effective RNAi. To validate the 
hypothesis, we first analyzed the activity of caspase-4 in 
target and non-target cells. Subsequently, we produced a 
peptide-inhibited siRNA carrying caspase-4 substrate at 
the 5’end of the antisense strand and analysed its chemical 
structure before testing the cell-specific biological activity 
of the described peptide-inhibited siRNA targeting GFP as 
well as STAT3 expression. Finally, we investigated the 
influence of PI-siRNA targeting STAT3 on the 
proliferation of JEG-3 target cells.  
 
Peptide-siRNA coupling 
A general challenge is to find a chemical strategy for 
efficiently coupling a peptide to an siRNA without 
degrading the siRNA. The F-moc strategy applied to 
protect side groups of the peptide lead to correct coupling 
to the aminohexyl-linker of the siRNA as analysed by 
MALDI-TOF mass spectrometry. Gel electrophoresis 
showed high coupling efficacy of the chemical strategy. 
 
Various cell types show different caspase-4 activity  
Caspase-4 is a cysteine protease and is believed to be an 
inflammatory caspase, along with caspase-1 and caspase-5 
(Yi et al, 2009). Presumably, caspase-4 is not involved in 
apoptotic processes. Its expression is increased in highly 
invasive and proliferatives choriocarcinoma and 
embryonic trophoblast cells compared to lower invasive 
control cell types (Fitzgerald et al, 2005). Even though 
caspase-4 is expressed in multiple cancer cells, it is not 
clear whether or not a correlation exists between 
prevention of apotosis in cancer cells, cancer development 
and caspase-4 expression and/or activity (Xie et al, 2008; 
Jiang et al, 2009; Kim et al, 2009). 
 
In the present work, we investigated whether the cell-
specific activity of caspase-4 could be exploited for 
activation of siRNA inhibited by a target peptide for 
caspase-4 bound covalently to the siRNA antisense strand. 
In our experiments we used two different cell lines: JEG-3 
cells displaying high caspase-4 activity, and HEK cells 
with nearly inactive caspase-4. Despite the claim that 
commercially available caspase substrates are not 
necessarily cleaved by the respective enzyme (Berger et al, 
2006), we showed a cell-specific cleavage of the substrate 
used. It can thus be concluded that PI-siRNA carrying the 
same peptide should be cleaved in a cell-specific manner.  
 
siRNA-peptide-chimera induce cell-specific RNAi 
Most strategies to induce cell specific RNAi apply siRNA 
in the form of a suitable non-covalently bound complex 
since, after delivery, these structures will release an 
unmodified siRNA (Simeoni et al, 2003; Crombez et al, 
2007; Krajcik et al, 2008). Covalently-bound siRNA 
chimera contained, however, unstable disulfide-bounds, 
which were cleaved after delivery to the cells (Detzer et al, 
2009). Stable modifications of the siRNA are in most 
cases confined to the sense strand of the siRNA and are 
rather small to avoid any influence on RISC complex 
formation. Our data indicate that a sequence of five amino 
acids covalently bound to the antisense strand of a siRNA 
is sufficient to inhibit its biological activity. This is 
confirmed by findings showing that the biological activity 
of 18-21bp siRNA exceeds that of larger RNA molecules 
(Elbashir et al, 2001; Scherr et al, 2003). As expected, the 
peptide-inhibited  siRNA  did  not  show  activity  in  HEK  428 
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Figure 7. Time-dependent STAT3 protein expression in JEG-3 
and HEK cells after transfection of conventional siRNAs and PI-
siRNAs. Conventional as well as peptide-inhibited siRNAs were 
delivered into JEG-3 and HEK cells. After 48hr, 72hr and 96hr 
STAT3 protein was detected by western blot. α-tubulin was used 
as loading control. A. Displays the arithmetic mean of 3 
independent western blots and the calculated standard error of 
STAT3 protein content in JEG-3 cells. B. Data of HEK cells are 
shown. The STAT3 content of the control-siRNA sample was 
standardized to 100%. 
 
 
 
 
 
 
Figure 8. Analyses of STAT3 silencing by PI-siRNA after 
caspase-4 inhibition. Conventional as well as PI-siRNA were 
delivered into JEG-3 cells together with a specific caspase-4 
inhibitor. After 48hr STAT3 expression was analyzed. As a 
loading control and for calculation of STAT3 protein content, α-
tubulin was measured. 
 
 
cells, which do not express the specific peptidase (caspase-
4) to cleave the peptide from the siRNA. In JEG-3 cells 
exhibiting caspase-4 activity the PI-siRNAs were able to 
silence gene expression, indicating that the peptide was 
cleaved from the siRNA. Interestingly, 48hr after delivery 
the PI-siRNAs did not reach the same biological activity 
as conventional siRNA. 
To validate that this is a time-dependent effect due to the 
fact that the peptide has first to be cleaved from the siRNA 
before RNAi and not an artifact induced by the Glycin 
residue on the linker or the linker structure itself, gene 
expression was measured after 48hr, 72hr and 96hr. 
Moreover, an insufficient PI-siRNA delivery into non-
target cells could result in an apparent cell-specific effect 
in non-target cells. Therefore, a chemical delivery strategy 
was used instead of electroporation. These experiments 
had four major results: (i) PI- siRNAs remain stable and 
inactive in non-target HEK cells; (ii) PI-siRNAs show 
their maximal silencing effect 72hr after delivery, which is 
slower than conventional siRNAs and is expected due to 
the time consuming cleavage process; (iii) PI-siRNAs and 
conventional siRNAs display the same silencing effect, 
and; (iv) the cell-specific effect of PI-siRNA was not due 
to insufficient delivery. 
 
The finding that the induction of RNAi by PI-siRNA 
occurs at a later time point than by conventional siRNA is 
supported by recent data that suggest a maximal cleavage 
capacity of caspase-4 around 4-10hr after contact with its 
target peptide (Koehn et al, 2008). 
 
Since the antisense 5’phosphate group binds to RISC it 
will be topic of further investigations how a siRNA 
carrying a glycine and a linker structure at the 5’end is 
incorporated into RISC and is able to induce RNAi. 
 
Differential gene silencing of STAT3 restricts tumor 
growth in vitro 
In previous work it was shown that STAT3 is a crucial 
regulator of embryonal trophoblast invasion during human 
pregnancy and that its constitutive activation is often 
correlated with extensive tumor invasion and poor 
therapeutic outcome (Rebouissou et al, 2009; Ren et al, 
2009; Thoennissen et al, 2009). In earlier studies it was 
found that silencing of STAT3 in JEG-3 choriocarcinoma 
cells reduces their invasive capacity and was not correlated 
with the induction of apoptosis (Poehlmann et al, 2005). In 
the present study, proliferative properties of JEG-3 cells 
were reduced when STAT3 expression was silenced. This 
effect can be induced, in an analogous manner, both by 
conventional siRNAs and by PI-siRNAs. Since 
proliferation was measured 72hr after siRNA delivery, 
these findings additionally support that the efficacy of PI-
siRNAs and conventional siRNA was comparable.  
 
PI-siRNA controls 
In the presented work for all experiments a negative 
siRNA control sequence and a positive GFP or STAT3 
siRNA sequence was used. The authors acknowledge that 
a second PI-siRNA control targeting GFP or STAT3 
expression that is not cleaved in any of the used cell lines 
would be useful. The challenge in this regard was to find a 
peptide sequence that was not cleaved by any other 
cytoplasmatic peptidase of the cells other than caspase-4 
and at the same time has the same charge and size as the 
caspase-4 target peptide applied. 
 
To validate if the cell specific gene silencing by PI-
siRNAs was due to caspase-4 activation, a caspase-4 
inhibitor was delivered into JEG-3 cells together with PI-429 
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siRNAs. This way it was clearly shown, that the effects of 
the presented PI-siRNA were caspase-4 dependent.  
 
CONCLUSIONS 
 
The present work provides a model for targeted, cell-
specific activation of peptide-inhibited siRNAs. This new 
tool might be useful for RNAi applications in co-cultures 
in vitro, but further development may also lead to 
applications  in vivo. Combined with established 
technologies of target cell-specific siRNA delivery, this 
technology might reduce side-effects of siRNAs in non-
target cells and lead to increased cell-specificity in 
therapeutic applications. 
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LIST OF ABBREVIATIONS 
 
DCC; N,N'-Dicyclohexylcarbodiimide 
DIEA; N,N-diisopropylethylamine  
DMF; (N, N-Dimethylformamide)  
Fmoc-Leu-F; aminoacid Leucine containing protecting fmoc 
groups 
HBSS; Hank's Buffered Salt Solution 
HBTU; (2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate) 
H-D(OFm)G-OH; peptide DG containing protecting fmoc groups 
H-E(OFm)V-OH ; peptide EV containing protecting fmoc groups 
NHS; N-Hydroxysuccinimid  
PBS; Phosphate buffered saline  
PI-siRNA; peptide-inhibited-peptidase-activated siRNA  
TFA; trifluoroacetic acid 
TFFH; Tetramethylfluoroformamidinium hexafluorophosphate 
 
REFERENCES 
 
Allerson CR, Sioufi N, Jarres R et al.  2005. Fully 2′-modified 
oligonucleotide duplexes with improved in vitro potency and 
stability compared to unmodified small interfering RNA. J Med 
Chem, 48, 901-904. 
Ananda K, Gopi HN and Babu VV. 2000. Convenient and 
efficient synthesis of Boc-/Z-/Fmoc-[beta]-amino acids 
employing N-protected [alpha]-amino acid fluorides. J Pep Res, 
55, 289-294. 
Berger AB, Kelly BS and Bogyo M. 2006. Commonly used 
caspase inhibitors designed based on substrate specificity 
profiles lack selectivity. Cell Res, 16, 961-963.  
Carpino LA and El-Faham A. 1995. Tetramethylfluoro-
formamidinium hexafluorophosphate: A rapid-acting peptide 
coupling reagent for solution and solid phase peptide synthesis. 
J Am Chem Soc, 117, 5401-5402. 
Chiu Y and Rana TM. 2003. siRNA function in RNAi: A 
chemical modification analysis. RNA, 9,1034-1048. 
Crombez L, Charnet A, Morris MC et al. 2007. A non-covalent 
peptide-based strategy for siRNA delivery. Biochem Soc Trans, 
35, 44-46. 
Detzer A, Overhoff M and Wünsche W. 2009. Increased RNAi is 
related to intracellular release of siRNA via a covalently 
attached signal peptide. RNA, 15, 627-636.  
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and 
Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate 
RNA interference in cultured mammalian cells. Nature, 411, 
494-498.  
Elbashir SM, Lendeckel W and Tuschl T. 2001. RNA 
interference is mediated by 21- and 22-nucleotide RNAs. Genes 
Dev, 15, 188-200. 
Elmen J, Thonberg H, Ljungberg K et al. 2005. Locked nucleic 
acid (LNA) mediated improvements in siRNA stability and 
functionality. Nucleic Acids Res, 33, 439-447. 
Fitzgerald JS, Tsareva SA, Poehlmann TG et al. 2005. Leukemia 
inhibitory factor triggers activation of signal transducer and 
activator of transcription 3, proliferation, invasiveness, and 
altered protease expression in choriocarcinoma cells. Int J 
Biochem Cell Biol, 37, 2284-2296. 
Hammond SM, Boettcher S, Caudy AA, Kobayashi R and 
Hannon GJ. 2001. Argonaute2, a link between genetic and 
biochemical analyses of RNAi. Science, 293, 1146-1150. 
Jiang CC, Mao ZG, Avery-Kiejda KA et al. 2009. Glucose-
regulated protein 78 antagonizes cisplatin and adriamycin in 
human melanoma cells. Carcinogenesis, 30, 197-204. 
Khvorova A, Reynolds A and Jayasena SD. 2003. Functional 
siRNAs and miRNAs exhibit strand bias. Cell, 115, 209-216.  
Kim YR, Kim KM, Yoo NJ and Lee SH. 2009. Mutational 
analysis of CASP1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 14 genes in 
gastrointestinal stromal tumors. Hum Pathol, 40, 868-71. 
Koehn S, Trueck M, Poehlmann TG et al. 2008. Assessment of 
caspase-4 released free AFC by RP-HPLC and fluorescence 
detection. J Chromatogr B Analyt Technol Biomed Life Sci, 
874, 111-114.  
Krajcik R, Jung A, Hirsch A, Neuhuber W and Zolk O. 2008. 
Functionalization of carbon nanotubes enables non-covalent 
binding and intracellular delivery of small interfering RNA for 
efficient knock-down of genes. Biochem Biophys Res 
Commun, 2, 595-602.  
Leuschner PJ, Ameres SL, Kueng S and Martinez J. 2006. 
Cleavage of the siRNA passenger strand during RISC assembly 
in human cells. EMBO Rep, 7, 314-320. 
Liu J, Carmell MA, Rivas FV et al. 2004. Argonaute2 is the 
catalytic engine of mammalian RNAi. Science, 305, 1437-1441.  
Lorenz C, Hadwiger P, John M, Vornlocher HP and Unverzagt 
C. 2004. Steroid and lipid conjugates of siRNAs to enhance 
cellular uptake and gene silencing in liver cells. Bioorg Med 
Chem Lett, 14, 4975-4977.  
Mack PC, Burich RA, Axentiev P, Gandara DR and Devere 
White RW. 2005. Inhibition of BCL-2 by Stealth siRNA results 
in growth suppression of LNCaP cells. J Clin Oncol, 23, 9626. 
Maniataki E and Mourelatos Z. 2005. A human, ATP-
independent, RISC assembly machine fueled by pre-miRNA. 
Genes Dev, 19, 2979-2990.  
Martinez J, Patkaniowska A, Urlaub H, Luhrmann R and Tuschl 
T. 2002. Single-stranded antisense siRNAs guide target RNA 
cleavage in RNAi. Cell, 110, 563-574.  
Martinon F and Tschopp J. 2007. Inflammatory caspases and 
inflammasomes: master switches of inflammation. Cell Death 
Differ, 14, 10-22. 
Matranga C, Tomari Y, Shin C, Bartel DP and Zamore PD. 2005. 
Passenger-strand cleavage facilitates assembly of siRNA into 
Ago2-containing RNAi enzyme complexes. Cell, 123, 607-620. 
McNamara JO, 2nd, Andrechek ER, Wang Y et al.  2006. Cell 
type-specific delivery of siRNAs with aptamer-siRNA 
chimeras. Nat Biotechnol, 24, 1005-1015.  430 
 
©The Authors | Journal of RNAi and Gene Silencing | December 2010 | Vol 6, No 2 | 422-430 | OPEN ACCESS 
Müller B, Besser D, Kleinwächter P, Arad O and Reissmann S. 
1999. Synthesis of N-carboxyalkyl and N-aminoalkyl 
functionalized dipeptide building units for the assembly of 
backbone cyclic peptides. J Pep Res, 54, 383-393. 
Muratovska A and Eccles MR. 2004. Conjugate for efficient 
delivery of short interfering RNA (siRNA) into mammalian 
cells. FEBS Letts, 558, 63-68.  
Poehlmann TG, Fitzgerald JS, Meissner et al. 2005. Trophoblast 
invasion: tuning through LIF, signalling via Stat3. Placenta, 26 
Suppl A, S37-41. 
Rand TA, Petersen S, Du F and Wang X. 2005. Argonaute2 
cleaves the anti-guide strand of siRNA during RISC activation. 
Cell, 123, 621-629.  
Rebouissou S. Amessou M, Couchy G et al. 2009. Frequent in-
frame somatic deletions activate gp130 in inflammatory 
hepatocellular tumours. Nature, 8, 200-204.  
Ren LN, Li QF, Xiao FJ et al. 2009. Endocrine glands-derived 
vascular endothelial growth factor protects pancreatic cancer 
cells from apoptosis via upregulation of the myeloid cell 
leukemia-1 protein. Biochem Biophys Res Commun, 14, 35-39. 
Scherr M, Morgan MA and Eder M. 2003. Gene silencing 
mediated by small interfering RNAs in mammalian cells. Curr 
Med Chem, 10, 245-256. 
Schulz JG, David G and Hassan BA. 2009. A novel method for 
tissue-specific RNAi rescue in Drosophila. Nucleic Acids Res, 
37, e93. 
Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N and Zamore 
PD. 2003. Asymmetry in the assembly of the RNAi enzyme 
complex. Cell, 115, 199-208.  
Simeoni F, Morris MC, Heitz F and Divita G. 2003. Insight into 
the mechanism of the peptide-based gene delivery system 
MPG: implications for delivery of siRNA into mammalian 
cells. Nucleic Acids Res, 31, 2717-2724. 
Soutschek J, Akinc A, Bramlage B et al. 2004. Therapeutic 
silencing of an endogenous gene by systemic administration of 
modified siRNAs. Nature, 432, 173-178.  
Thoennissen NH, Iwanski GB, Doan NB et al. 2009. Cucurbitacin 
B induces apoptosis by inhibition of the JAK/STAT pathway and 
potentiates antiproliferative effects of gemcitabine on pancreatic 
cancer cells. Cancer Res, 15, 5876-5884. 
Yutaka I and Kazunari T. 2006. Ligand-Targeted Delivery of 
Therapeutic siRNA. Pharm Res, 23, 8. 
Vollmer J, Jepsen JS, Uhlmann E et al. 2004. Modulation of CpG 
oligodeoxynucleotide-mediated immune stimulation by locked 
nucleic acid (LNA). Oligonucleotides, 14, 23-31. 
Xie SQ, Zhang ZQ, Hu GQ, Xu M and Ji BS. 2008. HL-37, a 
novel anthracene derivative, induces Ca(2+)-mediated 
apoptosis in human breast cancer cells. Toxicology, 254, 68-74. 
Yi JY, Hirabayashi Y, Choi YK et al. 2009. Benzene activates 
caspase-4 and -12 at the transcription level, without an 
association with apoptosis, in mouse bone marrow cells lacking 
the p53 gene. Arch Toxicol, 83, 795-803. 
 